PRME
Price
$3.34
Change
+$0.22 (+7.05%)
Updated
Sep 3 closing price
Capitalization
595.44M
57 days until earnings call
RLYB
Price
$0.58
Change
+$0.02 (+3.57%)
Updated
Sep 3 closing price
Capitalization
23.5M
63 days until earnings call
Interact to see
Advertisement

PRME vs RLYB

Header iconPRME vs RLYB Comparison
Open Charts PRME vs RLYBBanner chart's image
Prime Medicine
Price$3.34
Change+$0.22 (+7.05%)
Volume$2.35M
Capitalization595.44M
Rallybio
Price$0.58
Change+$0.02 (+3.57%)
Volume$1.83M
Capitalization23.5M
PRME vs RLYB Comparison Chart in %
Loading...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RLYB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PRME vs. RLYB commentary
Sep 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PRME is a Hold and RLYB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 04, 2025
Stock price -- (PRME: $3.34 vs. RLYB: $0.58)
Brand notoriety: PRME and RLYB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PRME: 52% vs. RLYB: 47%
Market capitalization -- PRME: $595.44M vs. RLYB: $23.5M
PRME [@Biotechnology] is valued at $595.44M. RLYB’s [@Biotechnology] market capitalization is $23.5M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.69B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PRME’s FA Score shows that 0 FA rating(s) are green whileRLYB’s FA Score has 1 green FA rating(s).

  • PRME’s FA Score: 0 green, 5 red.
  • RLYB’s FA Score: 1 green, 4 red.
According to our system of comparison, both PRME and RLYB are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PRME’s TA Score shows that 2 TA indicator(s) are bullish while RLYB’s TA Score has 4 bullish TA indicator(s).

  • PRME’s TA Score: 2 bullish, 4 bearish.
  • RLYB’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, RLYB is a better buy in the short-term than PRME.

Price Growth

PRME (@Biotechnology) experienced а -2.62% price change this week, while RLYB (@Biotechnology) price change was -2.07% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.29%. For the same industry, the average monthly price growth was +15.06%, and the average quarterly price growth was +30.89%.

Reported Earning Dates

PRME is expected to report earnings on Oct 31, 2025.

RLYB is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+0.29% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PRME($595M) has a higher market cap than RLYB($23.5M). PRME YTD gains are higher at: 6.849 vs. RLYB (-41.927). RLYB has higher annual earnings (EBITDA): -43.29M vs. PRME (-197.38M). PRME has more cash in the bank: 102M vs. RLYB (45.7M). RLYB has less debt than PRME: RLYB (58K) vs PRME (120M). PRME has higher revenues than RLYB: PRME (4.96M) vs RLYB (761K).
PRMERLYBPRME / RLYB
Capitalization595M23.5M2,532%
EBITDA-197.38M-43.29M456%
Gain YTD6.849-41.927-16%
P/E RatioN/AN/A-
Revenue4.96M761K652%
Total Cash102M45.7M223%
Total Debt120M58K206,897%
FUNDAMENTALS RATINGS
PRME: Fundamental Ratings
PRME
OUTLOOK RATING
1..100
55
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
38
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
PRMERLYB
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
86%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
81%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
88%
Advances
ODDS (%)
N/A
Bullish Trend 17 days ago
87%
Declines
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 6 days ago
86%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
74%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RLYB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
IFS40.190.47
+1.18%
Intercorp Financial Services
NNVC1.400.01
+0.72%
NanoViricides
WRLD169.92-1.51
-0.88%
World Acceptance Corp
PSA288.18-6.41
-2.18%
Public Storage
KRRO22.20-0.87
-3.79%
Korro Bio

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
-3.70%
CRSP - PRME
58%
Loosely correlated
+1.60%
BEAM - PRME
54%
Loosely correlated
-0.31%
RXRX - PRME
53%
Loosely correlated
-0.85%
CRBU - PRME
48%
Loosely correlated
+0.53%
EDIT - PRME
46%
Loosely correlated
-3.89%
More

RLYB and

Correlation & Price change

A.I.dvisor indicates that over the last year, RLYB has been loosely correlated with PROK. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if RLYB jumps, then PROK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RLYB
1D Price
Change %
RLYB100%
+3.89%
PROK - RLYB
45%
Loosely correlated
-2.54%
ATXS - RLYB
38%
Loosely correlated
+6.63%
PRME - RLYB
37%
Loosely correlated
-3.70%
ARTV - RLYB
37%
Loosely correlated
-1.90%
PMVP - RLYB
33%
Loosely correlated
+6.43%
More